Not sure there's merit in an AstraZeneca-Gilead merger, expert says

John Rountree, partner at Novasecta, discusses reports that British pharmaceutical giant AstraZeneca has approached U.S. firm Gilead Sciences to discuss a potential merger.
02:09
Mon, Jun 8 20204:46 AM EDT